Living With Prostate Cancer

Common hormonal treatments linked to abnormal heart rhythms and sudden death in men being treated for prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Treatments for advanced prostate cancer that suppress testosterone, a hormone (also called an androgen) that drives the malignant cells to grow and spread, are collectively referred to as androgen deprivation therapies, or ADT. These therapies can significantly extend lifespans in men who have the disease, but they also have a range of challenging side effects. […]

Highly accurate test reveals recurring prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

After being treated for prostate cancer, some men will experience a rise in PSA levels suggesting that new tumors lurk somewhere in the body. Finding these tiny cancerous deposits before they grow and spread any further is crucially important. But it’s also a challenge, since the budding tumors might be too small to see with […]

African American men respond better to treatments for advanced prostate cancer in clinical trials

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Racial differences have long been evident in prostate cancer statistics. In particular, African American men are diagnosed with prostate cancer more often than white men, and they’re also nearly twice as likely to die of the disease. But new research also shows that African American men who receive the most advanced treatments for late-stage prostate […]

Diet and exercise limit heart disease risk in men undergoing hormonal treatments for advanced prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Men with advanced prostate cancer are typically treated with drugs that prevent the body from making or using testosterone. A hormone (or an androgen, as it’s known), testosterone drives prostate cancer cells to grow faster, so shutting it down is essential to keeping the illness in check. About 600,000 men with advanced prostate cancer in […]

Hormonal therapy for aggressive prostate cancer: How long is enough?

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Men weighing treatment options for intermediate- or high-risk cancer that is still localized to the prostate can face a tricky question. A standard approach in these cases is to give radiation to the prostate along with drugs that block testosterone, a hormone that makes the cancer cells grow faster. For how long should this hormone […]

Long-term statin use protects against prostate cancer death

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Statins and other drugs that lessen cardiovascular disease risk by lowering blood lipids rank among the world’s most prescribed medications. And for the men who take them, accumulating evidence has for years pointed to another added benefit: a lower risk of developing prostate cancer. Now researchers are reporting that long-term statin use (more than 10 […]

Investigators unveil metastatic prostate cancer’s genomic landscape

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Localized prostate cancer that is diagnosed before it has a chance to spread typically responds well to surgery or radiation. But when a tumor metastasizes and sends malignant cells elsewhere in the body, the prognosis worsens. Better treatments for men with metastatic prostate cancer are urgently needed. In 2018, scientists advanced toward that goal by […]

A mix of treatments may extend life for men with aggressive prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

For men diagnosed with aggressive cancer that’s confined to the prostate and nearby tissues, the overarching goal of treatment is to keep the disease from spreading (or metastasizing) in the body. Doctors can treat these men with localized therapies, such as surgery and different types of radiation that target the prostate directly. And they can […]

Newer drugs are improving survival for men with metastatic prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Men with prostate cancer that has spread outside the gland now have several newer drug options available for treatment, and research has found that taking any of them is likely to improve survival duration.

New study downplays potential risk of dementia and Alzheimer’s disease among elderly men treated with hormonal therapy for prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

The male hormone testosterone contributes to normal brain function, and some research links memory loss in older men to testosterone declines that occur naturally with aging. However, testosterone is also like jet fuel for prostate tumors, causing them to grow faster, so during cancer treatment doctors will often give hormonal therapies that suppress its activities […]